论文部分内容阅读
ELISA 法检测27例急性早幼粒细胞白血病患者(APL)血清白细胞介素2受体(sIL-2R)水平.结果表明APL 患者血清sIL-2R 高于正常对照(P<0.01),经维甲酸治疗后逐渐降低,但治疗中期患者血清sIL-2R 仍高于正常和治疗后(缓解期)患者血清sIL-2R(P<0.05)。治疗后血清sIL-2R 虽略高于正常对照。却已恢复正常范围(P<0.05)。同时发现治疗中WBC 却明显升高,治疗后又下降,L-CFU 数随治疗逐渐降低并与病情同步变化。经相关分析,L-CFU 与血清sIL-2R 成正向相关(r=0.737)(P<0.01),而与WBC总数无明显相关性(P>0.05)。
Serum interleukin 2 receptor (sIL-2R) levels were measured by ELISA in 27 patients with acute promyelocytic leukemia (APL). The results showed that serum sIL-2R was significantly higher in patients with APL than in controls (P <0.01) After treatment, the serum sIL-2R level was still lower than that of normal and post-treatment (remission) serum sIL-2R (P <0.05). After treatment serum sIL-2R slightly higher than the normal control. Has returned to normal range (P <0.05). Also found that treatment was significantly increased WBC, decreased after treatment, L-CFU with the treatment gradually decreased and with the disease changes simultaneously. Correlation analysis showed that L-CFU had a positive correlation with serum sIL-2R (r = 0.737) (P <0.01), but not with the total number of WBC (P> 0.05).